retire

Novartis Chief Executive Jimenez to Retire in 2018, Narasimhan Named Successor

Joseph Jimenez (l) will retire next year and be succeeded by Vasant (Vas) Narasimhan, MD.​ BASEL, Switzerland—Novartis AG (NYSE: NVS) chief executive officer Joseph Jimenez, who has led the company since 2010, announced Monday that he plans to step down as CEO in January and retire from the company on Aug. 31, 2018. The pharma company, which also owns Alcon, said its board of directors has appointed Vasant (Vas) Narasimhan, MD, the company’s global head of drug development and chief medical officer, to succeed Jimenez, effective Feb. 1, 2018. Dr. Narasimhan, a member of the company’s executive committee, joined Novartis…